Supreme Court agrees to consider challenge against common abortion drug in 2024
Kaelan Deese
Video Embed
The Supreme Court agreed to take up a case on Wednesday focused on a common abortion pill manufacturer after a lower court put in place restrictions on how the drug should be used and distributed.
The case surrounds mifepristone maker Danco Laboratories, and it follows months of litigation that stemmed from a federal district judge’s decision in Texas in April to suspend the Food and Drug Administration‘s approval of the pill.
RUDY GIULIANI DEFAMATION SUIT: JUDGE CHASTISES FORMER MAYOR FOR CONDUCT OUTSIDE COURT
A panel on the 5th Circuit rolled back part of the Texas judge’s ruling by keeping the original FDA approval in place as well as the agency’s authorization of the pill’s generic form.
Mifepristone is expected to remain on the market while the high court considers the case.
Last year, the 6-3 Republican-appointed majority made the historic decision to overturn the precedent set under Roe v. Wade, allowing states to impose stricter rules on access to abortion in the case known as Dobbs v. Jackson Women’s Health Organization.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
A decision over the drug’s approval ahead of the 2024 presidential election will likely add a new dynamic for voters considering who to choose as president, as President Joe Biden has championed access to abortion and chastised the Supreme Court’s conservative supermajority that was installed by former President Donald Trump, his likely 2024 challenger.
This is a developing story and will be updated.